Intra-Cellular Therapies Inc [ITCI] stock is trading at $65.45, up 0.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ITCI shares have gain 1.68% over the last week, with a monthly amount drifted -13.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 19, March 2024, Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes. In a post published today on Yahoo Finance, Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the position of President. Mr. Halstead is currently serving as Executive Vice President and General Counsel. In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation. He will continue to report to Dr. Sharon Mates, Chairman and Chief Executive Officer.
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on January 03, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $83. Previously, TD Cowen started tracking the stock with Outperform rating on December 11, 2023, and set its price target to $75. On April 20, 2023, Morgan Stanley initiated with a Overweight rating and assigned a price target of $80 on the stock. Goldman downgraded its rating to a Neutral and decreased its price target to $49 on August 22, 2022. Mizuho initiated its recommendation with a Buy and recommended $74 as its price target on July 07, 2022. UBS started tracking with a Buy rating for this stock on June 14, 2022, and assigned it a price target of $75. In a note dated April 22, 2022, Piper Sandler initiated an Neutral rating and provided a target price of $59 on this stock.
Intra-Cellular Therapies Inc [ITCI] stock has fluctuated between $44.90 and $76.11 over the past year. Currently, Wall Street analysts expect the stock to reach $67 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $65.45 at the most recent close of the market. An investor can expect a potential return of 2.37% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
Intra-Cellular Therapies Inc [NASDAQ:ITCI] reported sales of 464.37M for the trailing twelve months, which represents a growth of 50.34%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.23 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.99 points at the first support level, and at 62.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 66.79, and for the 2nd resistance point, it is at 68.13.
Intra-Cellular Therapies Inc [ITCI] reported earnings per share of -$0.3 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.44/share, meaning a difference of $0.14 and a surprise factor of 31.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.25 per share as compared to estimates of -$0.57 per share, a difference of $0.32 representing a surprise of 56.10%.
Ratios To Look Out For
For context, Intra-Cellular Therapies Inc’s Current Ratio is 5.41. Further, the Quick Ratio stands at 5.31, while the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 13.64, the price to book ratio is 10.67.
Transactions by insiders
Recent insider trading involved Mates Sharon, Chairman, President & CEO, that happened on Mar 11 ’24 when 20565.0 shares were sold. SVP of Finance, CFO, Hineline Lawrence J. completed a deal on Mar 11 ’24 to sell 10121.0 shares. Meanwhile, EVP and General Counsel Halstead Michael sold 7345.0 shares on Mar 11 ’24.
